£103.81

Springer TRAIL, Fas Ligand, TNF and TLR3 in Cancer: 12 (Resistance to Targeted Anti-Cancer Therapeutics, 12)

Price data last checked 137 day(s) ago - refreshing...

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

About as cheap as it gets. The only time it was cheaper was 1 year ago.

£104 today · all-time low £103 (Jun 2024) · usually the usual

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey
↓ Forecast
where the price is heading next
↓ Statistics
all-time high & low, recent range
↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 594 days • 594 data points (No recent data available)

Historical
Generating forecast...
£113.57 £102.28 £104.75 £107.21 £109.67 £112.13 £114.60 10 June 2024 05 November 2024 02 April 2025 28 August 2025 24 January 2026

Price Distribution

Price distribution over 594 days • 4 price levels

Days at Price
Current Price
59 days · current 142 days 270 days 123 days 0 68 135 203 270 £104 £106 £107 £113 Days at Price

Price Analysis

Most common price: £107 (270 days, 45.5%)

Price range: £104 - £113

Price levels: 4 different prices over 594 days

Description

This volume provides the current understanding of death receptor's/TLR3 signaling regulation in cancer. Death receptors, including TRAIL-R1, TRAIL-R2, Fas and TNF-RI, owing to their ability to trigger apoptosis and to contribute to the elimination of cancer cells by the immune system have been considered, to variable extent, as important therapeutic targets for cancer therapy. But an increasing body of evidence suggests that some of these receptors may also contribute to tumorigenesis, or that new players such as TLR3 may be targeted for cancer therapy due to their ability to behave like death receptors.

Product Specifications

Barcode

No barcode data available

Similar Products You Might Like

Death Receptors and Cognate Ligands in Cancer: 49 (Results and Problems in Cell Differentiation, 49)
95% match

Death Receptors and Cognate Ligands in Cancer: 49 (Results and Problems in Cell Differentiation, 49)

Springer

£143.56 21 Jan 2026
Death Receptors in Cancer Therapy (Cancer Drug Discovery and Development)
95% match

Death Receptors in Cancer Therapy (Cancer Drug Discovery and Development)

Humana

£60.94 24 Jan 2026
Death Receptors and Cognate Ligands in Cancer: 49 (Results and Problems in Cell Differentiation, 49)
95% match

Death Receptors and Cognate Ligands in Cancer: 49 (Results and Problems in Cell Differentiation, 49)

Springer

£139.23 13 Jan 2026
Springer - Molecular Mechanisms of Tumor Cell Resistance
95% match

Springer - Molecular Mechanisms of Tumor Cell Resistance

Springer

£93.87 19 Apr 2026
TRAIL, Fas Ligand, TNF and TLR3 in Cancer: 12 (Resistance to Targeted Anti-Cancer Therapeutics, 12)
94% match

TRAIL, Fas Ligand, TNF and TLR3 in Cancer: 12 (Resistance to Targeted Anti-Cancer Therapeutics, 12)

Springer

£110.28 11 Mar 2026
Advances in Cancer Research: Vol. 74: Volume 74
94% match

Advances in Cancer Research: Vol. 74: Volume 74

Academic Press

£74.88 01 Mar 2026
Targeted Therapies: Mechanisms of Resistance (Molecular and Translational Medicine)
94% match

Targeted Therapies: Mechanisms of Resistance (Molecular and Translational Medicine)

Humana

£80.39 07 Apr 2026
Mechanisms of Tumor Escape from the Immune Response (Tumor Immunology and Immunotherapyseries, 1)
94% match

Mechanisms of Tumor Escape from the Immune Response (Tumor Immunology and Immunotherapyseries, 1)

CRC Press

£79.41 08 Mar 2026
Targeted Therapies: Mechanisms of Resistance (Molecular and Translational Medicine)
94% match

Targeted Therapies: Mechanisms of Resistance (Molecular and Translational Medicine)

Humana

£102.99 04 Apr 2026
Springer - Immunotherapy of Cancer: An Innovative Treatment
94% match

Springer - Immunotherapy of Cancer: An Innovative Treatment

Springer

£110.34 18 Apr 2026
Cell Death Signaling in Cancer Biology and Treatment (Cell Death in Biology and Diseases)
94% match

Cell Death Signaling in Cancer Biology and Treatment (Cell Death in Biology and Diseases)

Humana

£80.09 02 Apr 2026
Apoptosis in Cancer Pathogenesis and Anti-cancer Therapy: New Perspectives and Opportunities: 930 (Advances in Experimental Medicine and Biology, 930)
94% match

Apoptosis in Cancer Pathogenesis and Anti-cancer Therapy: New Perspectives and Opportunities: 930 (Advances in Experimental Medicine and Biology, 930)

Springer

£120.60 08 Jan 2026
Resistance of Targeted Therapies Excluding Antibodies for Lymphomas: 17 (Resistance to Targeted Anti-Cancer Therapeutics, 17)
94% match

Resistance of Targeted Therapies Excluding Antibodies for Lymphomas: 17 (Resistance to Targeted Anti-Cancer Therapeutics, 17)

Springer

£78.10 01 Mar 2026
Cancer Immunology: A Translational Medicine Context
94% match

Cancer Immunology: A Translational Medicine Context

Springer

£116.13 27 Feb 2026
Inflammation and Immunity in Cancer
94% match

Inflammation and Immunity in Cancer

Springer

£112.86 08 Mar 2026
Molecular Targeting and Signal Transduction: 119 (Cancer Treatment and Research, 119)
94% match

Molecular Targeting and Signal Transduction: 119 (Cancer Treatment and Research, 119)

Springer

£36.38 10 Mar 2026
Immuno-Oncology: Cellular and Translational Approaches (Methods in Pharmacology and Toxicology)
93% match

Immuno-Oncology: Cellular and Translational Approaches (Methods in Pharmacology and Toxicology)

Humana

£84.27 28 Feb 2026
Advances in Cancer Research (Volume 75)
93% match

Advances in Cancer Research (Volume 75)

Academic Press

£82.63 01 Mar 2026
Targeted Cancer Immune Therapy
93% match

Targeted Cancer Immune Therapy

Springer

£145.51 11 Jan 2026
Signal Transduction in Cancer: 115 (Cancer Treatment and Research, 115)
93% match

Signal Transduction in Cancer: 115 (Cancer Treatment and Research, 115)

Springer

£105.16 07 Jan 2026
Tumor Antigens Recognized by T Cells and Antibodies: 3 (Tumour Immunology and Immunotherapy Series)
93% match

Tumor Antigens Recognized by T Cells and Antibodies: 3 (Tumour Immunology and Immunotherapy Series)

CRC Press

£188.36 08 Mar 2026
Cancer Drug Resistance: Overviews and Methods: 1395 (Methods in Molecular Biology, 1395)
93% match

Cancer Drug Resistance: Overviews and Methods: 1395 (Methods in Molecular Biology, 1395)

Humana

£87.47 24 Feb 2026
Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors
93% match

Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors

Springer

£156.60 12 Jan 2026
Springer - Novel Immunotherapeutic Approaches to Cancer Treatment
93% match

Springer - Novel Immunotherapeutic Approaches to Cancer Treatment

Springer

£113.48 18 Apr 2026